BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Clemizole (EPX-100) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Clemizole (EPX-100)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07879170-8988@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Clemizole (EPX-100): Phase 1 readout est. (NCT07879170)
DESCRIPTION:Clemizole (EPX-100)\, phase 1.\nStudy: A Single and Multiple As
 cending Dose Study of EPX-100 in Healthy Adult Participants\nEstimated pri
 mary completion: 30 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/clemizole-epx-100#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07879170
URL:https://assetmemo.bio/drug/clemizole-epx-100#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04462770-8988@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Clemizole (EPX-100): Phase 3 readout est. (NCT04462770)
DESCRIPTION:Clemizole (EPX-100)\, phase 3\, Epilepsy.\nStudy: A Study of EP
 X-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/clemizole-epx-100#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04462770
URL:https://assetmemo.bio/drug/clemizole-epx-100#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
